A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma - Trial NCT06296121
Access comprehensive clinical trial information for NCT06296121 through Pure Global AI's free database. This Phase 3 trial is sponsored by Biocad and is currently Recruiting. The study focuses on Multiple Myeloma. Target enrollment is 252 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Biocad
Timeline & Enrollment
Phase 3
Dec 21, 2023
Jul 01, 2026
Primary Outcome
Overall response rate according to IMWG (International Myeloma Working Group) criteria
Summary
The aim of this study is to confirm the comparability of the efficacy and safety profiles of
 BCD-264 and Darzalex as monotherapy for relapsed and refractory multiple myeloma in subjects
 previously treated with proteasome inhibitors and immunomodulatory drugs, and who had disease
 progression on prior therapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06296121
Non-Device Trial